Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF Vaccine with Lenalidomide in Multiple Myeloma
NCT03376477Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2019
- Primary completion
- Jan 2024
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic myeloma vaccine in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2019; status: terminated.
02
Drugs
allogeneic myeloma vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03376477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03376477.